Daily consensus interferon versus peg-interferon alfa2b with weight based ribavirin in treatment-naive patients with chronic hepatitis C serotype-1
M Schuchmann, H Löhr, R Link, P Buggisch, M Fuchs, S Kaiser, C Antoni, T Witthöft, J Schlaak, P Galle, W Böcher · Zeitschrift für Gastroenterologie · 2007 · Heft 09
Bibliografische Angaben
Zusammenfassung
Introduction: Consensus interferon (CIFN) is a synthetic type 1 interferon with enhanced in vitro activity compared to conventional IFN-alfa (IFNa). In the prospective, randomized multicenter PegIntron-Against-Consensus-Trial (PACT), the efficacy and safety of daily CIFN-treatment and ribavirin is compared to PegInterferon (PegIFN) alfa2b plus ribavirin. At the meeting, we will present final results of all 291 patients treated with an induction or standard regimen of PegIFN alfa2b or consensus interferon, each combined with weight based ribavirin. Methods: 291 patients with chronic HCV serotype-1 infection were…
